Literature DB >> 19855263

The usefulness of preoperative dual-phase 99mTc MIBI-scintigraphy and IO-PTH assay in the treatment of secondary and tertiary hyperparathyroidism.

Guido Gasparri1, Michele Camandona, Ugo Bertoldo, Antonella Sargiotto, Mauro Papotti, Eleonora Raggio, Laura Nati, Paola Martino, Giulia Felletti, Giulio Mengozzi.   

Abstract

BACKGROUND: Persistent secondary or tertiary hyperparathyroidism (HPT) results from failure to remove enough hyperfunctioning parathyroid tissue. Ectopically situated parathyroid glands and supernumerary glands make failure more likely. Recurrent HPT after subtotal Ptx is usually due to regrowth of the remaining parathyroid tissue. Recurrence may also develop from a hyperplastic supernumerary gland or rarely from parathyromatosis. Recurrent HPT after total Ptx with autotransplantation is usually due to overgrowth of the autograft or for the previously mentioned reasons.
METHODS: Since 1995, 464 patients with SHPT or THPT were treated surgically; intraoperative parathormone (PTH) was measured in 277 patients. Sixty-eight patients also had a preoperative MIBI scan. We compared the preoperative MIBI scan results with intraoperative findings, parathyroid gland weight and histology. We questioned whether MIBI uptake corresponded to parathyroid gland size and weight. We also correlated the number of Ki67 nuclear positive cells with MIBI uptake. For SHPT in group I with 145 patients, neither intraoperative PTH (IO-PTH) assay nor MIBI scanning was done. In group II with 163 patients IO-PTH was used and in group III with 48 patients both IO-PTH and MIBI scanning was used. For THPT in group I with 42 patients, neither IO-PTH assay nor MIBI scanning was done. In group II with 46 patients IO-PTH was used and in group III with 20 patients both IO-PTH and MIBI scanning was used.
RESULTS: Parathyroid weight correlated directly with MIBI uptake. No correlation, however, occurred between MIBI uptake and parathyroid histology or between Ki67 staining and MIBI scanning. For SHPT in group I the persistence rate was 6.2% and recurrence rate 11%; in group II the persistence rate was 4.9% and recurrence rate 4.9%; in group III the persistence rate was 2%, and recurrence 4.2% (P < 0.05 between group I and III for persistence and recurrence). We obtained similar results in THPT, but recurrence was 0 in groups II and III, also when only 3 glands were removed, probably due to asymmetric hyperplasia commonly seen in this particular population (P < 0.05 regarding recurrence between group I and II-III, no difference between group II and III).
CONCLUSION: In conclusion our findings support that the surgeon experience is a very important factor for good results in patients with SHPT and THPT. Preoperative MIBI scanning and IO-PTH are helpful but not essential except in reoperations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19855263     DOI: 10.1097/SLA.0b013e3181b0c7f4

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  9 in total

1.  Intraoperative parathyroid hormone assay during surgery for secondary hyperparathyroidism: is it time to give up the chase at the hormone?

Authors:  Paolo Miccoli
Journal:  Endocrine       Date:  2012-12       Impact factor: 3.633

2.  Hyperparathyroidism, an emerging disease.

Authors:  Guido Gasparri; Nicola Palestini; Silvia Catalano; Francesca Talarico; Clemente Ronchetta; Gregorio Balbo; Michele Camandona
Journal:  Updates Surg       Date:  2010-11-13

3.  Current trends in surgery for renal hyperparathyroidism (RHPT)--an international survey.

Authors:  Philipp Riss; Reza Asari; Christian Scheuba; Bruno Niederle
Journal:  Langenbecks Arch Surg       Date:  2012-11-11       Impact factor: 3.445

4.  Recurrent primary hyperparathyroidism due to Type 1 parathyromatosis.

Authors:  Monica Jain; David L Krasne; Frederick R Singer; Armando E Giuliano
Journal:  Endocrine       Date:  2016-10-14       Impact factor: 3.633

5.  Diagnostic, therapeutic and healthcare management protocols in parathyroid surgery: II Consensus Conference of the Italian Association of Endocrine Surgery Units (U.E.C. CLUB).

Authors:  L Rosato; M Raffaelli; R Bellantone; A Pontecorvi; N Avenia; M Boniardi; M L Brandi; F Cetani; M G Chiofalo; G Conzo; M De Palma; G Gasparri; A Giordano; N Innaro; E Leopaldi; G Mariani; C Marcocci; P Marini; P Miccoli; P Nasi; F Pacini; R Paragliola; M R Pelizzo; M Testini; G De Toma
Journal:  J Endocrinol Invest       Date:  2014-01-09       Impact factor: 4.256

Review 6.  Parathyroid scintigraphy in renal hyperparathyroidism: the added diagnostic value of SPECT and SPECT/CT.

Authors:  David Taïeb; Pablo Ureña-Torres; Paolo Zanotti-Fregonara; Domenico Rubello; Alice Ferretti; Ioline Henter; Jean-François Henry; Francesca Schiavi; Giuseppe Opocher; Johan G Blickman; Patrick M Colletti; Elif Hindié
Journal:  Clin Nucl Med       Date:  2013-08       Impact factor: 7.794

7.  Use of intraoperative parathyroid hormone measurements during parathyroidectomy to predict postoperative parathyroid hormone levels in patients with renal hyperparathyroidism: meta-analysis.

Authors:  Dirk-Jan van Beek; Stina Fredriksson; Stefanie Haegele; Marco Raffaelli; Philipp Riss; Martin Almquist
Journal:  BJS Open       Date:  2022-01-06

8.  Sestamibi scan in renal parathyroidectomy: a worthwhile preoperative exam?

Authors:  Murilo Catafesta das Neves; Augusto Riedel Abrahão; Marcio Abrahão; Marcello Rosano; Lillian Andrade da Rocha; Hanna Karla Andrade Guapyassu Machado; Rodrigo Oliveira Santos
Journal:  Braz J Otorhinolaryngol       Date:  2020-11-16

9.  Localization of ectopic and supernumerary parathyroid glands in patients with secondary and tertiary hyperparathyroidism: surgical description and correlation with preoperative ultrasonography and Tc99m-Sestamibi scintigraphy.

Authors:  José Santos Cruz de Andrade; João Paulo Mangussi-Gomes; Lillian Andrade da Rocha; Monique Nakayama Ohe; Marcello Rosano; Murilo Catafesta das Neves; Rodrigo de Oliveira Santos
Journal:  Braz J Otorhinolaryngol       Date:  2014 Jan-Feb
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.